

# ARCHIMED HOPITAL - Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in hospital

Head :Leclerc-Zwirn Christel, Laboratoire GSK

Last update : 09/07/2020 | Version : 1 | ID : 141

## General

### Identification

Detailed name Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in hospital

Sign or acronym ARCHIMED HOPITAL

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL : 906317

### General Aspects

Medical area Hematology

Health determinants Medicine

Keywords pharmaco-epidemiology, thromboprophylaxis, fondaparinux, arixtra

### Scientific investigator(s) (Contact)

Name of the director Leclerc-Zwirn

Surname Christel

Phone +33 (0)1 39 17 86 96

Email christel.c.leclerc-zwirn@gsk.com

Unit Laboratoire GSK

### Collaborations

### Funding

Funding status Private

Details GSK laboratory

## Governance of the database

Sponsor(s) or organisation(s) responsible LABORATOIRE GSK

Organisation status Private

## Additional contact

## Main features

### Type of database

Type of database Study databases

Study databases (details) Longitudinal study (except cohorts)

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Medication(s) taken

Database recruitment is carried out as part of an interventional study No

Additional information regarding sample selection. All public and private hospitals that purchase ARIXTRA® 2.5 mg in metropolitan France will be solicited to participate in this study (source: database from the GlaxoSmithKline laboratory). Investigators will be the pharmacists of the hospitals that have accepted to participate in the study. Using the registry kept, the pharmacist will include the first 10 patients responding to the following criteria:

- ? Patient of at least 18 years of age,
- ? hospitalized in one of the establishment's care departments (excluding surgery departments), for whom a treatment via ARIXTRA® 2.5 mg is initiated with thromboprophylaxis

## Database objective

Main objective The main objective of this study is to evaluate the average duration of treatment via ARIXTRA® 2.5 mg at the hospital within the framework of the thromboprophylaxis indication

Inclusion criteria Using the registry kept, the pharmacist will include the first 10 patients responding to the following criteria:

- ? Patient of at least 18 years of age,

? hospitalized in one of the establishment's care departments (excluding surgery departments),  
? for whom a treatment via ARIXTRA® 2.5 mg is initiated with thromboprophylaxis

## Population type

Age  
Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered Sick population

Gender  
Male  
Woman

Geography area National

Detail of the geography area France

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY) 2009

Date of last collection (YYYY or MM/YYYY) 2011

### Size of the database

Size of the database (number of individuals) [500-1000[ individuals

Details of the number of individuals 680

### Data

Database activity Data collection completed

Type of data collected  
Clinical data  
Declarative data

Clinical data (detail) Medical registration

Declarative data (detail) Face to face interview

Presence of a biobank No

Health parameters studied	Health event/morbidity Health care consumption and services
Care consumption (detail)	Hospitalization Medicines consumption
<b>Procedures</b>	
Data collection method	During the first month following the set up of the study in the center, the pharmacist will log in a registry all of the prescription requests for ARIXTRA® 2.5 mg in thromboprophylaxis carried out by his establishment's care departments (excluding surgery departments). The pharmacist will identify the patients that should be included in the study according to the defined eligibility criteria. He will complete a specific inclusion questionnaire for the first 10 patients that meet the eligibility criteria. The pharmacist will complete for each patient included a follow-up questionnaire when released from the hospital.
Participant monitoring	Yes
Details on monitoring of participants	The data that will be collected in the follow-up questionnaire are: ? Premature interruption of the treatment, ? total duration of the administration of the treatment, ? prescriptions for prophylactic purposes after the treatment
Links to administrative sources	No
<b>Promotion and access</b>	
<b>Promotion</b>	
<b>Access</b>	
Terms of data access (charter for data provision, format of data, availability delay)	Publications in progress
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only